Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $13.05M rose 75.6% year over year, ahead of the +63.8% change in trailing-twelve-month research & development. Sequentially, it rose 74.7% from the prior quarter. Over 3 fiscal years it compounded at -10.3% a year.
Context
- Research & development amounted to 11.5% of revenue in FY2025, up 2.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +75.6% holds above the trailing-twelve-month pace of +63.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 32.51M USD
- Year-over-year change
- +56.4%
- 4-year CAGR
- -10.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.51M | +56.4% |
| FY2024 | 2024-12-31 | 20.79M | -58.1% |
| FY2023 | 2023-12-31 | 49.64M | +10.3% |
| FY2022 | 2022-12-31 | 44.99M | -12.0% |
| FY2021 | 2021-12-31 | 51.14M | — |
Research & Development vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's LTM Jun 2026 research & development of $39.85M is the lowest of the 10 companies compared; the peer median is $139.61M.
- Its year-over-year change of +63.8% is the highest of 9, against a peer median of +35.8%.
- Research & development amounts to 12.8% of revenue for AUPH, versus a peer median of 2390.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M | -8.4% | — | — |
EVMNEvommune, Inc. | LTM Mar 2026 | $77M | — | — | 770.0% |
| LTM Mar 2026 | $69.93M | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| FY2025 | $54.15M | +59.9% | — | 4011.3% | |
| LTM Jun 2026 | $39.85M | +63.8% | -10.3% | 12.8% | |
| Peer median (excluding AUPH) | $139.61M | +35.8% | +40.1% | 2390.7% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.61M | 134.03M | 175.51M | 235.13M | 283.06M |
| Cost of Revenue | 1.09M | 5.66M | 14.15M | 28.25M | 32.67M |
| Gross Profit | 44.51M | 128.37M | 161.37M | 206.89M | 250.39M |
| Gross Margin | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Research & Development | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M |
| Selling, General & Admin | 171.44M | 196.37M | 195.04M | 172.03M | 101.79M |
| Operating Expenses | 225.25M | 239.84M | 253.06M | 211.57M | 145.48M |
| Depreciation & Amortization | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M |
| EBITDA | (177.45M) | (103.65M) | (63.05M) | 31.73M | 127.76M |
| EBITDA Margin | -389.1% | -77.3% | -35.9% | 13.5% | 45.1% |
| Operating Income | (180.74M) | (111.47M) | (91.69M) | (4.69M) | 104.91M |
| Operating Margin | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
| Interest Income | 529K | 5.12M | 17M | 16.97M | 13.57M |
| Interest Expense | 0 | 0 | 2.78M | 4.84M | 4.33M |
| Other Income / Expenses | 529K | 5.12M | 14.22M | 12.14M | 9.24M |
| Income Before Tax | (180.21M) | (106.35M) | (77.47M) | 7.45M | 114.16M |
| Pre-Tax Margin | -395.1% | -79.3% | -44.1% | 3.2% | 40.3% |
| Income Tax Expense | 760K | 1.83M | 551K | 1.7M | (173.05M) |
| Net Income | (180.97M) | (108.18M) | (78.02M) | 5.75M | 287.2M |
| Net Margin | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
| EPS (Basic) | (1.40) | (0.76) | (0.54) | 0.04 | 2.14 |
| EPS (Diluted) | (1.40) | (0.76) | (0.54) | 0.04 | 2.07 |
| Weighted Avg Shares | 129.37M | 141.92M | 143.24M | 143.06M | 134.37M |
| Weighted Avg Shares (Diluted) | 129.37M | 141.92M | 143.24M | 146.19M | 138.7M |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.